1 week Ago By Defense World Staff
Cerity Partners LLC lessened its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 33.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The institutional investor owned 29,723 shares of the biotechnology company’s stock after selling 14,854 shares during the period. Cerity Partners LLC’s holdings in Coherus BioSciences were worth $40,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds have also recently made changes to their positions in CHRS.
Steph & Co. acquired a new position in shares of Coherus BioSciences in the 4th quarter valued at approximately $34,000. Intech Investment Management LLC bought a new stake in Coherus BioSciences during the fourth quarter worth $38,000.
Ieq Capital LLC bought a new stake in Coherus BioSciences during the fourth quarter worth $68,000. Wells Fargo & Company MN boosted its holdings in shares of Coherus BioSciences by 32.4% in the 4th quarter.
Wells Fargo & Company MN now owns 61,830 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 15,137 shares in the last quarter. Finally, Savant Capital LLC bought a new position in shares of Coherus BioSciences in the 4th quarter valued at $130,000. Institutional investors and hedge funds own 72.
82% of the company’s stock. Coherus BioSciences Trading Up 2.0 %Shares of CHRS stock opened at $1.
03 on Friday. The business’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.
12. Coherus BioSciences, Inc. has a 12 month low of $0.
66 and a 12 month high of $2.43. The firm has a market capitalization of $119.
37 million, a price-to-earnings ratio of -12.88 and a beta of 1.01.
Wall Street Analysts Forecast GrowthA number of research firms have issued reports on CHRS. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a research report on Tuesday, March 11th.
UBS Group restated a “neutral” rating and issued a $1.05 price target (down from $1.50) on shares of Coherus BioSciences in a research note on Thursday.
Finally, StockNews.com cut shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock.
According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.26.
Read Our Latest Stock Analysis on CHRSAbout Coherus BioSciences (Free Report)Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.Featured ArticlesFive stocks we like better than Coherus BioSciencesStock Average Calculator Markets Think Robinhood Earnings Could Send the Stock UpTop Biotech Stocks: Exploring Innovation OpportunitiesChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?What Do S&P 500 Stocks Tell Investors About the Market? AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround.
